Key facts
- This page summarizes John C. Thomas's Form 4 filing for Virios Therapeutics, Inc. (DWTX).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 20 Jun 2023, 14:01.
John C. Thomas - 15 Jun 2023 Form 4 Insider Report for Virios Therapeutics, Inc. (DWTX)
- Role
- Director
- Signature
- /s/ Greg Duncan, Attorney-in-Fact
- Issuer symbol
- DWTX
- Transactions as of
- 15 Jun 2023
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 20 Jun 2023, 14:01:31 UTC
- Previous filing
- 30 Jun 2022
- Next filing
- 28 Feb 2024
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
John C. Thomas filed Form 4 for Virios Therapeutics, Inc. (DWTX) on 20 Jun 2023.
Change
- Previous filing in this sequence was filed on 30 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
VIRI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +5,250
- Change %
- Price
- $0.000000
- Shares after
- 5,250
- Date
- 15 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,250
- Exercise price
- $1.85
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The stock option will vest 100% on June 15, 2024, one year following the grant date. |